Richard Law
Stock Analyst at Goldman Sachs
(2.89)
# 1,557
Out of 5,182 analysts
80
Total ratings
34.21%
Success rate
3.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Buy | $36 → $31 | $14.95 | +107.36% | 6 | Apr 7, 2026 | |
| BCAX Bicara Therapeutics | Maintains: Neutral | $14 → $16 | $21.12 | -24.24% | 1 | Mar 31, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $38 → $27 | $16.10 | +67.70% | 8 | Mar 18, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Neutral | $65 → $95 | $98.82 | -3.87% | 1 | Mar 3, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintains: Sell | $2 → $3 | $3.49 | -14.04% | 4 | Mar 2, 2026 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $30 → $34 | $32.24 | +5.46% | 4 | Mar 2, 2026 | |
| MLTX MoonLake Immunotherapeutics | Downgrades: Sell | $8 → $10 | $17.96 | -44.32% | 5 | Jan 15, 2026 | |
| RCUS Arcus Biosciences | Upgrades: Buy | $16 → $28 | $22.34 | +25.34% | 1 | Jan 13, 2026 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $67 | $39.44 | +69.88% | 2 | Jan 12, 2026 | |
| NUVL Nuvalent | Maintains: Buy | $120 → $135 | $102.74 | +31.40% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $29 | $24.21 | +19.79% | 2 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $52 | $26.62 | +95.34% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $4 → $3 | $5.73 | -47.64% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $30 | $34.26 | -12.43% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $17.48 | -37.07% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $27.43 | +71.35% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $51.22 | +23.00% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $85.05 | -56.50% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $13.49 | +463.38% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.94 | +376.19% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $10.82 | +463.77% | 4 | May 8, 2023 |
Viridian Therapeutics
Apr 7, 2026
Maintains: Buy
Price Target: $36 → $31
Current: $14.95
Upside: +107.36%
Bicara Therapeutics
Mar 31, 2026
Maintains: Neutral
Price Target: $14 → $16
Current: $21.12
Upside: -24.24%
Olema Pharmaceuticals
Mar 18, 2026
Maintains: Buy
Price Target: $38 → $27
Current: $16.10
Upside: +67.70%
Protagonist Therapeutics
Mar 3, 2026
Maintains: Neutral
Price Target: $65 → $95
Current: $98.82
Upside: -3.87%
Rocket Pharmaceuticals
Mar 2, 2026
Maintains: Sell
Price Target: $2 → $3
Current: $3.49
Upside: -14.04%
Celldex Therapeutics
Mar 2, 2026
Maintains: Neutral
Price Target: $30 → $34
Current: $32.24
Upside: +5.46%
MoonLake Immunotherapeutics
Jan 15, 2026
Downgrades: Sell
Price Target: $8 → $10
Current: $17.96
Upside: -44.32%
Arcus Biosciences
Jan 13, 2026
Upgrades: Buy
Price Target: $16 → $28
Current: $22.34
Upside: +25.34%
Crinetics Pharmaceuticals
Jan 12, 2026
Upgrades: Buy
Price Target: $67
Current: $39.44
Upside: +69.88%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $102.74
Upside: +31.40%
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $24.21
Upside: +19.79%
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $26.62
Upside: +95.34%
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $5.73
Upside: -47.64%
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $34.26
Upside: -12.43%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $17.48
Upside: -37.07%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $27.43
Upside: +71.35%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $51.22
Upside: +23.00%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $85.05
Upside: -56.50%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $13.49
Upside: +463.38%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.94
Upside: +376.19%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $10.82
Upside: +463.77%